Advanced Enzymes announces positive clinical breakthrough in the randomized controlled trials of systemic enzymes and probiotics to resolve ‘long COVID’ fatigue symptoms
Biznextindia : Advanced Enzyme Technologies Limited (AETL) has announced that its systemic enzyme and probiotic supplements—ImmunoSEB and ProbioSEB CSC3 have passed the promising stages of randomized controlled clinical trials in terms of efficacy to resolve post‐COVID fatigue symptoms.
Muscle fatigue and cognitive disturbances persist in patients after recovery from acute COVID‐19 disease. However, there are no specific treatments available globally to treat post‐COVID fatigue complications.
With an aim to evaluate the efficacy and safety of the health supplements ImmunoSEB (systemic enzyme complex) and ProbioSEB CSC3 (probiotic complex) in patients suffering from COVID‐19 induced fatigue, a randomized, multi‐centric, double blind and placebo‐controlled trial was conducted in 200 patients suffering from post‐COVID fatigue symptoms.
The test arm (100 patients) received the oral supplements for 14‐days and the control arm (100 patients) received placebo, informed Dr. Abhijit K. Rathi, Principal Scientist, AETL.
The randomized clinical trial was conducted on 200 patients that did not have an active SARS‐CoV‐2 infection, as determined by a negative COVID‐19 test, with a complaint of post‐COVID fatigue.
Patients were required to have a positive COVID‐19 test at any time in the past. The trial was conducted across three centres in India—Swasthya Hospital, Bhopal; Samvedna Hospital, Varanasi; and Chirayu Medical College & Hospital, Bhopal by Investigators for 14‐days, informed Dr Rathi.
According to the clinical research paper published by the Switzerland‐based “Medicines” Journal on August 30, 2021, the treatment efficacy was compared using the Chalder Fatigue Scale (CFQ‐11) for 14‐days. Interestingly, the supplemental treatment resulted in resolution of fatigue in a greater percentage in patients during the test as against the control arm (91% vs. 15%) during the 14‐day trial. Patients in the test arm category showed a significantly greater reduction the overall physical and mental fatigue scores as against patients in the control arm segment. The supplements were well tolerated with no adverse events reported. This clinical study demonstrated that the 14‐day supplementation of ImmunoSEB and ProbioSEB CSC3 resolved post‐COVID‐19 fatigue symptoms and improved patients’ functional status and quality of life, informed Dr. Rathi.
The Coronavirus disease‐19 (COVID‐19) caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), is a worldwide pandemic afflicting a large population across the globe. Most infected people develop acute symptoms that last for 7–10 days. However, one or more symptoms (physical, cognitive and/or psychological) persist for weeks or even months in a substantial percentage of people. Fatigue is the most persistent and debilitating symptom of long COVID.
“Enzymes and probiotics are a robust mechanism to revitalize stamina and vitality, which is proved during the recently concluded randomized clinical trials,” said Mr. Vasant Rathi, Chairman, AETL.